Hemodialysis Clinical Trial
— Pet TherapyOfficial title:
Investigation of Physiological and Psychological Effects of Robotic Cat and Betta Fish Therapies in Hemodialysis Patients: A Randomized Controlled Study
Verified date | November 2023 |
Source | Karadeniz Technical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The research was carried out as a randomized controlled trial to examine the physiological and psychological effects of robotic cat and Betta fish therapies in hemodialysis patients.
Status | Completed |
Enrollment | 54 |
Est. completion date | September 1, 2021 |
Est. primary completion date | July 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Being =18 years old, - Accepting to participate in the research, - Being literate, - Being able to communicate verbally, - Receiving outpatient hemodialysis treatment three times a week in the same institution, - Absence of any impairment in mental and cognitive functions, - Weight and height measurements can be made while standing, - Being on hemodialysis treatment for at least three months (33), - Being able to perform self-care activities independently, - Not having allergies for patients in the robot cat group, - Desiring to spend time with the robotic cat "Silver" during hemodialysis by the patients in the robot cat group, - Wanting to nutrition and care fish at home by patients in the betta fish group. Exclusion Criteria: - Refusal to participate in the research, - Being on peritoneal dialysis, - Being diagnosed with a psychiatric disorder diagnosed by a psychiatrist, - Unstable general condition (hemodynamically) (heart rate <60 beats/min, systolic blood pressure <100 mm/Hg or diastolic blood pressure <60 mm/Hg), - Patients with chronic obstructive pulmonary disease (COPD) (except Mild COPD Stage 1) and advanced heart failure were identified (34, 35). |
Country | Name | City | State |
---|---|---|---|
Turkey | Karadeniz Tecnical University | Trabzon |
Lead Sponsor | Collaborator |
---|---|
Karadeniz Technical University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body mass Index Monitoring | This form includes BMI, an anthropometric measurement. To obtain the Body Mass Index, the patient's body weight (kg) was divided by the square of the height (m) (BMI=kg/m2).
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated. |
16 week | |
Primary | De Jong Gierveld Loneliness Scale | The scale was first developed by De Jong Gierveld and Kamphuis in 1985. The Turkish adaptation of the scale with factor loadings between 0.64-0.86 was carried out by Çavdar, Bagci, Chorbaci, Saritas and Tasdelen in 2015. Social loneliness and emotional loneliness two sub-scale in size 11 items in Scale. It is a four-point likert (4=Very convenient, 3=Convenient, 2=Not convenient, 1=Not convenient at all) type scale. Since the items in the social loneliness dimension contain positive statements, these items are reverse items. As the score obtained from the scale increases, the levels of loneliness increase.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated. |
16 week | |
Primary | Subjective Happiness Scale (SHS) | Developed by Lyubomirsky and Lepper, SHD is a seven-point Likert type, self-report style. The scale consists of four items; Since the fourth item contains a negative statement, this item is the reverse item. The lowest score taken from the scale is four, the highest score is 28, and as the individual's scale score increases, the level of happiness increases.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated. |
16 week | |
Primary | End Stage Renal Disease (ESRD)-Adherence Questionnaire | This scale was developed by Kim, Evangelista, Phillips, Pavlish, and Kopple. The ESRD-Adaptation Scale consists of four compliance behaviors subscales: participation in treatment (1st, 3rd and 5th items), medicine use (6th item), fluid restriction (8th item), and dietary restriction (9th item). Items 2, 5 and 7 of the items do not have a point value. The range of scores that can be obtained from the scale is between 0-1200, and as the score increases, the compliance of the patients with the treatment also increases.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated. |
16 week | |
Primary | Dialysis Symptom Index (DSI) | Weisbord et al. has a total of 30 items in which both emotional and physical symptoms of dialysis patients and the severity of these symptoms are evaluated. After the patients answered yes-no to the questions regarding the symptoms they experienced within a week, their symptoms with a yes answer are re-evaluated in a five-point Likert type ("5 points: A lot", "4 points: Very little", "3 points: Sometimes", "2 points: A little", "1 point: Not at all"). The total score to be obtained from the scale ranges from 0 to 150.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated. |
16 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04892745 -
Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
|
||
Not yet recruiting |
NCT04925674 -
Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
|
Phase 1 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Withdrawn |
NCT02904343 -
Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study
|
N/A | |
Withdrawn |
NCT01855334 -
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
|
Phase 4 | |
Completed |
NCT01700465 -
Estimating and Predicting Hemodynamic Changes During Hemodialysis
|
N/A | |
Recruiting |
NCT01195519 -
The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis
|
N/A | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00527774 -
Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06351007 -
Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK)
|
N/A | |
Withdrawn |
NCT03664141 -
Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)
|
Phase 3 | |
Completed |
NCT03909698 -
Antibiotic Dosing in Patients on Intermittent Hemodialysis
|
||
Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT06098924 -
HD Patients' Depression and Happiness
|
||
Recruiting |
NCT03419923 -
Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage
|
N/A |